Simvastatin attenuates smooth muscle neointimal proliferation and pulmonary hypertension in rats - PubMed (original) (raw)
Comparative Study
. 2002 Nov 15;166(10):1403-8.
doi: 10.1164/rccm.200203-268OC. Epub 2002 Aug 15.
Affiliations
- PMID: 12406854
- DOI: 10.1164/rccm.200203-268OC
Comparative Study
Simvastatin attenuates smooth muscle neointimal proliferation and pulmonary hypertension in rats
Toshihiko Nishimura et al. Am J Respir Crit Care Med. 2002.
Abstract
Hypertensive pulmonary vascular disease is characterized by abnormal proliferation of vascular endothelial and smooth muscle cells, leading to occlusion of pulmonary arterioles, pulmonary hypertension, right ventricular failure, and death. Compounds with antiproliferative effects on vascular endothelial and smooth muscle cells, such as 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors, may prevent the development of experimental hypertensive pulmonary vascular disease. Pneumonectomized rats injected with monocrotaline at 7 days develop severe hypertensive pulmonary vascular disease with neointimal formation. Rats were randomized to receive either vehicle or treatment with the HMG-CoA reductase inhibitor simvastatin (2 mg/kg per day). By Day 35, rats that received vehicle had higher mean pulmonary arterial pressures (53 +/- 2 mm Hg) and right ventricular hypertrophy (right ventricle/[left ventricle plus septum] [RV/LV+S] = 0.78 +/- 0.09) than rats in Group PMS5-35 that received simvastatin from Day 5 to 35 (mean pulmonary arterial pressure = 27 +/- 3 mm Hg, RV/LV+S = 0.34 +/- 0.08; p < or = 0.001). Pulmonary vascular remodeling with neointimal formation consisting of vascular smooth muscle cells was more severe in vehicle-treated rats (vascular occlusion score, 1.98 +/- 0.02) than in Group PMS5-35 (vascular occlusion score, 0.59 +/- 0.46; p < 0.001). In addition, lung endothelial nitric oxide synthase gene expression was decreased in vehicle-treated animals but was restored toward normal levels in simvastatin-treated animals. Simvastatin attenuates monocrotaline-induced pulmonary vascular remodeling with neointimal formation, pulmonary arterial hypertension, and right ventricular hypertrophy in rats.
Comment in
- Therapy of pulmonary hypertension: the evolution from vasodilators to antiproliferative agents.
Rubin LJ. Rubin LJ. Am J Respir Crit Care Med. 2002 Nov 15;166(10):1308-9. doi: 10.1164/rccm.2208008. Am J Respir Crit Care Med. 2002. PMID: 12421739 No abstract available.
Similar articles
- Simvastatin rescues rats from fatal pulmonary hypertension by inducing apoptosis of neointimal smooth muscle cells.
Nishimura T, Vaszar LT, Faul JL, Zhao G, Berry GJ, Shi L, Qiu D, Benson G, Pearl RG, Kao PN. Nishimura T, et al. Circulation. 2003 Sep 30;108(13):1640-5. doi: 10.1161/01.CIR.0000087592.47401.37. Epub 2003 Sep 8. Circulation. 2003. PMID: 12963647 - The HMG-CoA reductase inhibitor, pravastatin, prevents the development of monocrotaline-induced pulmonary hypertension in the rat through reduction of endothelial cell apoptosis and overexpression of eNOS.
Guerard P, Rakotoniaina Z, Goirand F, Rochette L, Dumas M, Lirussi F, Bardou M. Guerard P, et al. Naunyn Schmiedebergs Arch Pharmacol. 2006 Sep;373(6):401-14. doi: 10.1007/s00210-006-0082-1. Epub 2006 Aug 1. Naunyn Schmiedebergs Arch Pharmacol. 2006. PMID: 16896805 - Additive effect of tadalafil and simvastatin on monocrotaline-induced pulmonary hypertension rats.
Zhang WH, Liu CP, Zhang YJ, Ji YQ, Lu WX, Zeng Q. Zhang WH, et al. Scand Cardiovasc J. 2012 Dec;46(6):374-80. doi: 10.3109/14017431.2012.729272. Epub 2012 Sep 28. Scand Cardiovasc J. 2012. PMID: 22971207 - Pathology and pathobiology of pulmonary hypertension.
Guignabert C, Dorfmuller P. Guignabert C, et al. Semin Respir Crit Care Med. 2013 Oct;34(5):551-9. doi: 10.1055/s-0033-1356496. Epub 2013 Sep 13. Semin Respir Crit Care Med. 2013. PMID: 24037624 Review. - Vascular effects of HMG CoA-reductase inhibitors (statins) unrelated to cholesterol lowering: new concepts for cardiovascular disease.
Lefer AM, Scalia R, Lefer DJ. Lefer AM, et al. Cardiovasc Res. 2001 Feb 1;49(2):281-7. doi: 10.1016/s0008-6363(00)00247-9. Cardiovasc Res. 2001. PMID: 11164838 Review. No abstract available.
Cited by
- Pathogenic mechanisms of pulmonary arterial hypertension.
Chan SY, Loscalzo J. Chan SY, et al. J Mol Cell Cardiol. 2008 Jan;44(1):14-30. doi: 10.1016/j.yjmcc.2007.09.006. Epub 2007 Sep 20. J Mol Cell Cardiol. 2008. PMID: 17950310 Free PMC article. Review. - Current Treatment Strategies and Nanoparticle-Mediated Drug Delivery Systems for Pulmonary Arterial Hypertension.
Nakamura K, Akagi S, Ejiri K, Yoshida M, Miyoshi T, Toh N, Nakagawa K, Takaya Y, Matsubara H, Ito H. Nakamura K, et al. Int J Mol Sci. 2019 Nov 23;20(23):5885. doi: 10.3390/ijms20235885. Int J Mol Sci. 2019. PMID: 31771203 Free PMC article. Review. - Combination of Dichloroacetate and Atorvastatin Regulates Excessive Proliferation and Oxidative Stress in Pulmonary Arterial Hypertension Development via p38 Signaling.
Li T, Li S, Feng Y, Zeng X, Dong S, Li J, Zha L, Luo H, Zhao L, Liu B, Ou Z, Lin W, Zhang M, Li S, Jiang Q, Qi Q, Xu Q, Yu Z. Li T, et al. Oxid Med Cell Longev. 2020 Jun 11;2020:6973636. doi: 10.1155/2020/6973636. eCollection 2020. Oxid Med Cell Longev. 2020. PMID: 32617141 Free PMC article. - Pulmonary vascular disease related to hemodynamic stress in the pulmonary circulation.
Chan SY, Loscalzo J. Chan SY, et al. Compr Physiol. 2011 Jan;1(1):123-39. doi: 10.1002/cphy.c090004. Compr Physiol. 2011. PMID: 23737167 Free PMC article. Review. - Statins inhibit pulmonary artery smooth muscle cell proliferation by upregulation of HO-1 and p21WAF1.
Li M, Liu Y, Shi H, Zhang Y, Wang G, Xu J, Lu J, Zhang D, Xie X, Han D, Wu Y, Li S. Li M, et al. Naunyn Schmiedebergs Arch Pharmacol. 2012 Oct;385(10):961-8. doi: 10.1007/s00210-012-0768-5. Epub 2012 Jul 22. Naunyn Schmiedebergs Arch Pharmacol. 2012. PMID: 22820842
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical